157 related articles for article (PubMed ID: 27668365)
1. A Multidisciplinary Approach to Standardizing Processes for Blinatumomab Administration.
DePadova S; Howlett C; Rivera K
Clin J Oncol Nurs; 2016 Oct; 20(5):466-9. PubMed ID: 27668365
[TBL] [Abstract][Full Text] [Related]
2. Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia.
Turner J; Schneider SM
Clin J Oncol Nurs; 2016 Apr; 20(2):165-8. PubMed ID: 26991709
[TBL] [Abstract][Full Text] [Related]
3. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
Dahl J; Mace M; Kantarjian H; Jabbour E
Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).
Friberg G; Reese D
Ann Oncol; 2017 Aug; 28(8):2009-2012. PubMed ID: 28379283
[No Abstract] [Full Text] [Related]
5. Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958
[TBL] [Abstract][Full Text] [Related]
6. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
7. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
8. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
Marini BL; Sun Y; Burke PW; Perissinotti AJ
J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
[TBL] [Abstract][Full Text] [Related]
9. Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges.
Bernhardt MB; Militano O; Honeyford L; Zupanec S
J Oncol Pharm Pract; 2021 Mar; 27(2):376-388. PubMed ID: 33334253
[TBL] [Abstract][Full Text] [Related]
10. Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy.
Kuchimanchi M; Zhu M; Clements JD; Doshi S
Br J Clin Pharmacol; 2019 Apr; 85(4):807-817. PubMed ID: 30645768
[TBL] [Abstract][Full Text] [Related]
11. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
12. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
Wilke AC; Gökbuget N
Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
[TBL] [Abstract][Full Text] [Related]
13. How we infuse blinatumomab.
Oranges K; Windawi S; Powell S; Dallago D; Escobar N; Rheingold SR
Pediatr Blood Cancer; 2020 Sep; 67(9):e28541. PubMed ID: 32573958
[No Abstract] [Full Text] [Related]
14. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
[TBL] [Abstract][Full Text] [Related]
15. Addressing Administration Challenges Associated With Blinatumomab Infusions: A Multidisciplinary Approach.
Szoch S; Boord C; Duffy A; Patzke C
J Infus Nurs; 2018; 41(4):241-246. PubMed ID: 29958260
[TBL] [Abstract][Full Text] [Related]
16. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Bumma N; Papadantonakis N; Advani AS
Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
[TBL] [Abstract][Full Text] [Related]
17. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
Dombret H; Topp MS; Schuh AC; Wei AH; Durrant S; Bacon CL; Tran Q; Zimmerman Z; Kantarjian H
Leuk Lymphoma; 2019 Sep; 60(9):2214-2222. PubMed ID: 30947585
[TBL] [Abstract][Full Text] [Related]
18. Application of Medicare's New Technology Add-on Payment Program for Blinatumomab.
Dhruva SS; Prasad V
JAMA Oncol; 2016 Feb; 2(2):165-6. PubMed ID: 26720844
[No Abstract] [Full Text] [Related]
19. Real-world experience managing blinatumomab toxicities in adults with relapsed/refractory acute lymphoblastic leukemia.
Crist M; Emadi A; Duffy A
J Oncol Pharm Pract; 2020 Jul; 26(5):1080-1085. PubMed ID: 31635546
[TBL] [Abstract][Full Text] [Related]
20. Blinatumomab: first global approval.
Sanford M
Drugs; 2015 Feb; 75(3):321-7. PubMed ID: 25637301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
